Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S54-7. Epub 2011 Sep 27.


Objectives: To evaluate the clinical response after switching from infliximab to adalimumab in patients with Behçet's disease (BD).

Methods: In this ongoing, prospective, longitudinal and observational study, data were collected on efficacy and safety of every patient with BD beginning anti-TNF therapy in the last 8 years. The present analysis was restricted to patients who were switched to adalimumab after failing or not tolerating infliximab.

Results: A total of 69 patients with BD have been treated with infliximab so far. Seventeen of these (25%) have been switched to adalimumab for lack or loss of efficacy or infusion reactions. In 10 out of these 17, the main manifestations requiring switching were the mucocutaneous lesions, in 4 retinal vasculitis and in 3 the neurological involvement. Of the 17 treated patients, 9 showed sustained remission of the disease and 3 a good response. No side effects were observed in any patient.

Conclusions: The results of our study suggest that patients with BD showing a scarce response or adverse events to infliximab may successfully be treated with adalimumab, regardless of the reason for switching.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / immunology
  • Drug Resistance / immunology
  • Female
  • Humans
  • Infliximab
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • Remission Induction
  • Treatment Failure
  • Treatment Outcome
  • Young Adult


  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Infliximab
  • Adalimumab